Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (111-120 of 487) with videos related to

Pageof 49
Sort By:
Journal of Breast Cancer|October 17, 2014
Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA MutationRishi Agarwal, Kimberly Koenig, Eric Rohren, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 27, 2016
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside reportVivek Subbiah, David S Hong, Funda Meric-Bernstam
Frontiers in Medicine|December 2, 2022
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227Peter M Anderson, Vivek Subbiah, Matteo M Trucco
The Lancet. Oncology|July 3, 2025
Bridging tumour classification and treatmentVivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, et al.
JCO Precision Oncology|September 11, 2020
Precision Oncology in Sarcomas: Divide and ConquerRoberto Carmagnani Pestana, Roman Groisberg, Jason Roszik, et al.
Diagnostics (Basel, Switzerland)|February 18, 2017
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future PerspectivesVivek Subbiah, Hubert H Chuang, Dhiraj Gambhire, et al.
Journal of Medical Case Reports|November 27, 2007
Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case reportVivek Subbiah, Uyen K Ly, Amer Khiyami, et al.
The Lancet. Oncology|March 3, 2022
ROAR trial: which treatment is effective after progression? - Authors' replyPatrick Y Wen, Paul Burgess, Palanichamy Ilankumaran, et al.
Nature Reviews. Cancer|June 1, 2026
Mutation-centric kinase drug repurposing for rare cancersMarina Chan, Haiching Ma, Vivek Subbiah, et al.
JCO Precision Oncology|May 4, 2022
Activity of Pemigatinib in Pilocytic Astrocytoma and <i>FGFR1</i><sup></sup> MutationStephen Capone, Leena Ketonen, Shiao-Pei Weathers, et al.
Pageof 49

Showing results (111-120 of 487) with videos related to

Sort By:
Pageof 49
Journal of Breast Cancer|October 17, 2014
Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA MutationRishi Agarwal, Kimberly Koenig, Eric Rohren, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 27, 2016
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside reportVivek Subbiah, David S Hong, Funda Meric-Bernstam
Frontiers in Medicine|December 2, 2022
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227Peter M Anderson, Vivek Subbiah, Matteo M Trucco
The Lancet. Oncology|July 3, 2025
Bridging tumour classification and treatmentVivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, et al.
JCO Precision Oncology|September 11, 2020
Precision Oncology in Sarcomas: Divide and ConquerRoberto Carmagnani Pestana, Roman Groisberg, Jason Roszik, et al.
Diagnostics (Basel, Switzerland)|February 18, 2017
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future PerspectivesVivek Subbiah, Hubert H Chuang, Dhiraj Gambhire, et al.
Journal of Medical Case Reports|November 27, 2007
Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case reportVivek Subbiah, Uyen K Ly, Amer Khiyami, et al.
The Lancet. Oncology|March 3, 2022
ROAR trial: which treatment is effective after progression? - Authors' replyPatrick Y Wen, Paul Burgess, Palanichamy Ilankumaran, et al.
Nature Reviews. Cancer|June 1, 2026
Mutation-centric kinase drug repurposing for rare cancersMarina Chan, Haiching Ma, Vivek Subbiah, et al.
JCO Precision Oncology|May 4, 2022
Activity of Pemigatinib in Pilocytic Astrocytoma and <i>FGFR1</i><sup></sup> MutationStephen Capone, Leena Ketonen, Shiao-Pei Weathers, et al.
Pageof 49